글로벌 신장세포암 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

국립암연구소에 따르면 RCC의 5년 생존율은 70%가 넘습니다. 신세포암은 가장 빠르게 성장하는 고형 종양 암 중 하나입니다. 신세포암에 대한 이해와 치료를 지배하는 임상 패러다임은 지난 수십 년 동안 극적으로 바뀌었습니다. 신세포암은 성인에서 8번째로 흔한 암으로, 전 세계적으로 모든 새로운 암 사례의 3%에서 4%를 차지합니다. 다양한 유명 연구 기관에서 신세포암이 남성에서 7번째로 흔한 암이고 여성에서 9번째로 흔한 암이라고 계산했습니다.

Data Bridge Market Research는 신세포암 시장이 2021년에 6억 3,540만 달러 규모였으며 2029년까지 1,005,110,000 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 5.90%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

신세포암은 진행된 단계에서 전신 치료에 특히 저항성이 있는 암입니다. 진보된 수술적 치료와 혁신적인 약물, 그리고 임상적으로 안정적인 질병 상태의 확장으로 인해 환자 생존율이 향상되었습니다. 초음파, 컴퓨터 단층 촬영(CT), 자기 공명 영상과 같은 복부 영상의 광범위한 사용으로 인해 작고 우연한 신장암의 비율이 극적으로 증가했습니다(MRI). 전이성 및 진행된 RCC에서 현재 치료 환경은 TKI 및 mTOR 억제제에서 면역 체크포인트 억제제(ICI)와 같은 특수 면역 종양학 약물로 전환될 것입니다. 이는 단일 요법(Opdivo) 또는 복합 요법(Opdivo+Yervoy)으로 PFS에 유리한 결과를 보였습니다.

신장세포암 시장 동향

운전자

• 암 유병률 증가

암 유병률 증가는 신세포암 시장의 성장률을 높일 것으로 추정됩니다. 세계보건기구(WHO)에 따르면 암은 전 세계적으로 가장 큰 사망 원인으로, 2020년에는 약 1,000만 명이 사망했으며, 사망자 6명 중 1명에 가깝습니다. 이와 함께 후천성 낭포성 신장 질환과 C형 간염 의 증가로 신세포암 위험이 증가하여 시장 성장률이 더욱 높아질 것입니다.  

• 의료 인프라에 대한 투자 증가

신장세포암 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 노령 인구 증가

신세포암 시장에서 매출 성장을 주도하는 주요 이유 중 하나는 인구 고령화입니다. 신세포암은 또한 유아에서 노인에 이르기까지 환자 수가 적은 희귀 질환입니다. 그러나 이 질환은 60~70세 연령대에서 가장 흔히 나타나 발병 위험이 더 높다는 것을 나타냅니다.

Furthermore, increasing incidences of obesity and sedentary lifestyle of people such as growing addiction of smoking will expand the renal cell carcinoma market. Additionally, growing government initiatives to spread awareness and presence of favorable reimbursement policies are estimated to enhance the market’s growth rate.

Opportunities

• Increase in the number of research and development activities    

The renal cell carcinoma market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the renal cell carcinoma market growth. Manufacturers of kidney cancer diagnostic systems and healthcare service providers have begun to offer tailored patient care and access to complete end-to-end medical technology products and services for renal cell carcinoma kidney cancer treatment. They are working on product prototyping development and improvement, as well as minimizing operational expenses.

Moreover, increase in the number of emerging markets and rising technological advancement will further provide beneficial opportunities for the renal cell carcinoma market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the renal cell carcinoma market. Additionally, side effects linked with therapies such as heart problems, decreased red blood cell count, fatigue, weight loss, loss of hair, diarrhea, weight loss, decreased lung, kidney, and liver quality and others and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This renal cell carcinoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the renal cell carcinoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Renal cell carcinoma is more common in men than in women (by a factor of 2 or 3), and in those who have smoked in the past. It's also more common in those who have other kinds of kidney problems, and it runs in some families. Renal cell carcinoma is responsible for over 30,000 new instances of kidney cancer in the United States each year.

Renal cell carcinoma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Renal Cell Carcinoma Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.  In November of 2019, the globe was shocked to learn of the COVID-19 virus.  The COVID-19 pandemic, which was produced by the SARS-CoV-2 virus, had a significant health impact on renal cell carcinoma management and other urology disciplines. The high prevalence of surgery cancellations, including those related to renal cancer, will result in inevitable healthcare overload and, most likely, a deleterious impact on oncological outcomes, particularly in patients with locally advanced and metastatic renal cancer. On the bright side, the renal cell carcinoma market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Recent Development

• In January 2021, the Food and Drug Administration had announced the approval of combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC). Nivolumab 240 mg every two weeks (30-minute intravenous infusion) or 480 mg every four weeks (30-minute intravenous infusion) in conjunction with cabozantinib 40 mg orally once day without food until disease progression or unacceptable toxicity is achieved is the suggested dosage.

Global Renal Cell Carcinoma Market Scope

The renal cell carcinoma market is segmented on the basis of treatment, diagnosis, type, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Interferon-alfa
• Interleukin-2
• Biologics
• Ablation
• Targeted Therapy
• Axitinib
• Bevacizumab
• Cabozantinib
• Everolimus
• Lenvatinib
• Nivolumab
• Pazopanib
• Sorafenib
• Sunitinib
• Temsirolimus
• Chemotherapy
• Surgery
• Others

Diagnosis

• Urine Tests
• CT scan
• Nephrectomy
• Blood Tests
• Ultrasound
• Biopsy

Type

• Clear Cell RCC
• Papillary RCC
• Chromophobe RCC

Dosage Forms

• Capsule
• Tablets
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Renal Cell Carcinoma Market Regional Analysis/Insights

The renal cell carcinoma market is analysed and market size insights and trends are provided by country, treatment, diagnosis, type, dosage forms, route of administration, end-users and distribution channel as referenced above.

The countries covered in the renal cell carcinoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the renal cell carcinoma market because of the presence of key manufacture of the product and established regulatory framework in this region. Additionally, high demand of diseases specific treatment and surging adoption of newer technologies will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, growing number of generic drugs manufacturers will further cushion the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Renal Cell Carcinoma Market Share Analysis

The renal cell carcinoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to renal cell carcinoma market.

Some of the major players operating in the renal cell carcinoma market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• AbbVie Inc.(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)  
• 애벗(미국)
• 머크 KGaA(독일)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 히크마 제약(영국)
• Fresenius Kabi AG(독일)
• Amneal Pharmaceuticals LLC. (미국)

SKU-53398